Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Via Giacomo Venezian, 1, Milano 23100, Italy.
UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Roma 00168, Italy.
Crit Rev Oncol Hematol. 2024 Dec;204:104537. doi: 10.1016/j.critrevonc.2024.104537. Epub 2024 Oct 23.
Male breast cancer (MaBC) is an uncommon disease. It is generally assimilated to post-menopausal female breast cancer and treated accordingly. However, the real impact of radiation therapy, after both mastectomy and breast conservation, has yet to be established. We performed a systematic review and meta-analysis to assess the clinical impact of radiation therapy in MBC patients to support the clinical decision-making process and to inform future research. We performed a systematic search of 'male', 'breast', 'cancer', 'radiotherapy' and corresponding synonyms on PubMed/MEDLINE and EMBASE databases. We included interventional studies reporting on radiation therapy effect on overall survival (OS) in MBC patients. Reviews, editorials, letters to the editor, conference abstracts and case reports, and studies with less than 20 MaBC patients or without data on OS were excluded. We extracted relevant characteristics and outcomes for each study, including the hazard ratio (HR) for OS, after adjustment for potential confounders. We calculated an overall adjusted hazard ratio (aHR) for OS for patients receiving radiation therapy compared to those who did not. A random effect model was used. The search strategy yielded 10,260 articles. After removal of duplicates (n = 8254), 2006 articles remained and underwent abstract screening. A total of 168 manuscripts was selected for full text screening. After full text screening, 22 articles were included in the qualitative systematic review. Among them, 14 were included in the quantitative synthesis, reporting on 80.219 MaBC patients. A statistically significant reduction in the risk of death was observed for patients receiving radiation therapy, with a pooled aHR = 0.73 (95 %CI: 0.66-0.81) for OS. Significant heterogeneity among reported aHR estimates was seen (I2=77 %). A significant clinical benefit on OS has been observed when including radiation therapy in the therapeutic algorithm of patients with MaBC. These findings, which are based on retrospective studies and tumour registry reports, deserve further investigation to identify MaBC patient subgroups who most benefit from radiation therapy.
男性乳腺癌(MaBC)是一种罕见的疾病。它通常被归类为绝经后女性乳腺癌,并进行相应的治疗。然而,放射治疗对保乳术后和乳房切除术患者的实际影响尚未确定。我们进行了一项系统回顾和荟萃分析,以评估放射治疗对 MaBC 患者的临床影响,为临床决策过程提供支持,并为未来的研究提供信息。我们在 PubMed/MEDLINE 和 EMBASE 数据库中对“男性”、“乳房”、“癌症”、“放射治疗”及其同义词进行了系统搜索。我们纳入了报告放射治疗对 MaBC 患者总生存(OS)影响的干预性研究。综述、社论、给编辑的信、会议摘要和病例报告,以及 MaBC 患者少于 20 例或无 OS 数据的研究被排除在外。我们提取了每项研究的相关特征和结果,包括调整潜在混杂因素后 OS 的风险比(HR)。我们计算了接受放射治疗的患者与未接受放射治疗的患者的 OS 总调整后的危险比(aHR)。使用随机效应模型。搜索策略产生了 10260 篇文章。去除重复项(n=8254)后,剩余 2006 篇文章,并进行了摘要筛选。共有 168 篇手稿被选入全文筛选。经过全文筛选,22 篇文章被纳入定性系统综述。其中,14 篇文章纳入了定量综合分析,共纳入 80219 例 MaBC 患者。接受放射治疗的患者死亡风险显著降低,OS 的合并 aHR=0.73(95%CI:0.66-0.81)。报道的 aHR 估计值之间存在显著的异质性(I2=77%)。当将放射治疗纳入 MaBC 患者的治疗方案时,观察到 OS 有显著的临床获益。这些基于回顾性研究和肿瘤登记报告的发现值得进一步研究,以确定最受益于放射治疗的 MaBC 患者亚组。